Table of Contents Author Guidelines Submit a Manuscript
Journal of Nucleic Acids
Volume 2011 (2011), Article ID 154609, 5 pages
http://dx.doi.org/10.4061/2011/154609
Research Article

Commercially Supplied Amine-Modified siRNAs May Require Ultrafiltration prior to Conjugation with Amine-Reactive Compounds

Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia

Received 10 November 2010; Accepted 8 February 2011

Academic Editor: Daisuke Miyoshi

Copyright © 2011 Shannen Lau et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Juliano, M. R. Alam, V. Dixit, and H. Kang, “Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides,” Nucleic Acids Research, vol. 36, no. 12, pp. 4158–4171, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. P. J. White, “Barriers to successful delivery of short interfering RNA after systemic administration,” Clinical and Experimental Pharmacology and Physiology, vol. 35, no. 11, pp. 1371–1376, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. D. B. Rozema, D. L. Lewis, D. H. Wakefield et al., “Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 32, pp. 12982–12987, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. A. M. Derfus, A. A. Chen, D. H. Min, E. Ruoslahti, and S. N. Bhatia, “Targeted quantum dot conjugates for siRNA delivery,” Bioconjugate Chemistry, vol. 18, no. 5, pp. 1391–1396, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Jung, S. H. Lee, H. Mok, H. J. Chung, and T. G. Park, “Gene silencing efficiency of siRNA-PEG conjugates: effect of PEGylation site and PEG molecular weight,” Journal of Controlled Release, vol. 144, no. 3, pp. 306–313, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Lu, Q. P. Duan, L. Ma, and D. X. Zhao, “Chemical strategies for the synthesis of peptide-oligonucleotide conjugates,” Bioconjugate Chemistry, vol. 21, no. 2, pp. 187–202, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Muratovska and M. R. Eccles, “Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells,” FEBS Letters, vol. 558, no. 1–3, pp. 63–68, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Soutschek, A. Akinc, B. Bramlage et al., “Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs,” Nature, vol. 432, no. 7014, pp. 173–178, 2004. View at Publisher · View at Google Scholar
  9. F. Kratz, “Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles,” Journal of Controlled Release, vol. 132, no. 3, pp. 171–183, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. H. R. Kim, I. K. Kim, K. H. Bae, S. H. Lee, Y. Lee, and T. G. Park, “Cationic solid lipid nanoparticles reconstituted from low density lipoprotein components for delivery of siRNA,” Molecular Pharmaceutics, vol. 5, no. 4, pp. 622–631, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Sogami, S. Era, S. Nagaoka et al., “High-performance liquid chromatographic studies on non-mercapt a mercapt conversion of human serum albumin. II,” Journal of Chromatography A, vol. 332, pp. 19–27, 1985. View at Publisher · View at Google Scholar